WEDNESDAY, March 14 (HealthDay News) -- Yet a different orally taken medication shows some assurance in preventing relapse and disability since people with relapsing-remitting multiple sclerosis, a renovated report suggests.

In the new study, laquinimod reduced the annals relapse rate by 23 percent, and inability progression by 36 percent.

"We originate that laquinimod, as compared with placebo, reduced the asperse of relapse and slowed the progression of disability in patients with relapsing-remitting multiple sclerosis," the European researchers, led through Dr. Giancarlo Comi of the Institute of Experimental Neurology in Milan, wrote.

The study, what one. was funded by the drug's manufacturer, Teva Pharmaceutical Industries, was published in the March 15 upshot of the New England Journal of Medicine.

Multiple sclerosis (MS) is a ailment that damages the outside of resolution fibers in the central nervous body, according to the National Multiple Sclerosis Society. The brain, thorn and optic nerves make up the central full of nerves system. Symptoms of the disease have power to include fatigue, numbness in the limbs, remainder. and coordination problems, bladder or bowel dysfunction, illusion problems, pain and even paralysis, according to the fellowship.

Most patients -- about 85 percent -- own a form of MS that's called relapsing-remitting, the the community has reported. That means that the multitude have periods where the disease is highly active, and at other times the disease remits. During these periods of suspense, there may be complete or prejudiced recovery of function, and the distemper doesn't progress during remission, according to the copartnership.

All of the more than 1,100 men included in the current study had relapsing-remitting MS; the volunteers came from 139 sites in 24 countries. They were randomly assigned to retain a laquinimod pill or an inert placebo once daily for 24 months.

The occurring once a year relapse rate for those on the effective drug was 0.30 compared to 0.39 notwithstanding those on a placebo, a conquest in relapse of 23 percent in the place of those on the medication. During the study, 63 percent of those steady the drug remained relapse-free compared to 52 percent of those steady placebo.

Just over 11 percent of those taking laquinimod had confirmed disability progression compared to 15.7 percent of those forward placebo, the researchers found.

The medicine was generally well-tolerated. The ~ly significant side effects appeared to exist urinary tract infections and a short-lived abnormality in liver function tests.

This isn't the leading pill developed for MS. The capital was Gilenya, which was approved in 2010 in quest of the treatment of relapsing-remitting MS. This physic is currently under increased scrutiny in the United States and Europe for there have been 11 unexpected deaths in family taking the drug. Several other oral medications are in development. One is called teriflunomide, and it's too for the treatment of relapsing-remitting MS; its manufacturer lately filed for approval in the United States and Europe. Before Gilenya was approved, MS medications had to have ~ing given by injection.

"This is meaningful since it's a more convenient passage of taking medication. I don't take it it will differ significantly in potency from other agents. The safety given conditions looks good now, but many undignified-frequency side effects only become superficial [after a drug has been approved] in put in the ledger-marketing trials," said Dr. Malcolm Gottesman, most eminent of the division of neurology, co-manager of neuroscience and director of the Winthrop Comprehensive MS Care Center at Winthrop University Hospital in Mineola, N.Y.

"Right at present, it looks good. It looks like it works and is without anxiety to take," Gottesman said, adding that it's not going to be a groundbreaking change in treatment.

Timothy Coetzee, essential research officer for the MS company, said laquinimod works differently than the other pills and looks since if it might have some sheltering effects that other drugs don't overture, though more research is needed into that in posse aspect.

He said it's not innocent if laquinimod's modest effect on relapse rates is "clinically meaningful," which means, does it make a disagreement to someone living with MS? He said that if the manufacturer files ~ the sake of U.S. Food and drug Administration approval, "regulators are looking despite a clinically meaningful impact."

But, Coetzee added, "This study illustrates that in that place are oral agents becoming available with respect to people with MS. And, it brings waiting under the possibility of fulfilment that we will have a nearest generation of agents, and that we have power to hopefully stop the progression of MS."

More advice

Learn more about multiple sclerosis from the National Multiple Sclerosis Society.

@yahoonews without interrupti~ Twitter, become a fan on Facebook